Evidence map›Paper›PMID 31554697›Full record

ArticleMolecular pharmacology2019

Potential Regulation of UGT2B10 and UGT2B7 by miR-485-5p in Human Liver.

Aimee K Sutliff, Jian Shi, Christy J W Watson, Martina S Hunt, Gang Chen, Hao-Jie Zhu, Philip Lazarus

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Aimee K SutliffDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Jian ShiDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Christy J W WatsonDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Martina S HuntDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Gang ChenDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Hao-Jie ZhuDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.).
Philip LazarusDepartment of Pharmaceutical Sciences, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, Washington (A.K.S., C.J.W.W., M.H., G.C., P.L.); and Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, Michigan (J.S., H.-J.Z.) phil.lazarus@wsu.edu.
University of Michigan–Ann Arbor · USWashington State University Spokane · US

Funding

The UGT2A and 3A metabolizing enzymes and tobacco-related cancer riskR01ES025460 · NIEHS · WASHINGTON STATE UNIVERSITY · PI LAZARUS, PHILIP · 2015 to 2019
$2.8M
Genetic determinants of ACEI prodrug activationR01HL126969 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHU, HAOJIE · 2016 to 2020
$1.9M
NHLBI NIH HHS R01 HL126969NIEHS NIH HHS R01 ES025460
6 · The paper itself

Abstract

The UDP-glucuronosyltransferase (UGT) family of enzymes is important in the metabolic elimination of a variety of endogenous compounds such as bile acids, steroids, and fat-soluble vitamins, as well as exogenous compounds including many pharmaceuticals. The UGT2B subfamily is a major family of UGT enzymes expressed in human liver. The identification of novel mechanisms including post-transcriptional regulation by microRNA (miRNA) contributes to interindividual variability in UGT2B expression and is a crucial component in predicting patient drug response. In the present study, a high-resolution liquid chromatography-tandem mass spectrometry method was employed to measure UGT2B protein levels in a panel of human liver microsomal samples (

Indexed as

GlucuronosyltransferaseHEK293 CellsHumansLiverMicroRNAsProteomicsGlucuronosyltransferaseMicroRNAsMIRN485 microRNA, humanUGT2B10 protein, humanUGT2B7 protein, human

Identifiers

PMID31554697
PMCPMC6820218
OpenAlexW2975964442

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.